MOTS-c has no published human safety data. Not thin data — none. No trial has given it to a person and recorded what followed, so every side-effect list you find was assembled from something else.
Nobody knows what MOTS-c does to people, because no published trial has given it to one. Every human MOTS-c study measured the body's own peptide in blood — in 404 hepatitis B patients, in athletes, in carriers of a gene variant. The treatment studies are all in mice. An empty side-effect list is a measurement gap, not a safety record.
What the human data actually is
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, described in 2015. It circulates in human plasma and declines with age, which is the whole basis of the interest in it. Everything measured in people so far has been that circulating peptide, not an injected one.
- Hepatitis B, 2024. Blood levels compared across 85 healthy subjects and 404 patients. MOTS-c was used as a biomarker; the treatment experiments were in mice and cells.
- Exercise, 2021. Training raised endogenous MOTS-c in human muscle and blood. The animals were the ones that got injections — aged mice, dosed 3 times a week.
- Genetics, 2024. Male carriers of the K14Q variant, which weakens MOTS-c binding to its target kinase, showed higher rates of sarcopenia and type 2 diabetes.
- Myostatin, 2021. Plasma MOTS-c ran inversely to myostatin in human subjects — a correlation, in people who were not dosed with anything.
In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation.
Reynolds et al., Nature Communications, 2021That is a genuinely interesting body of work, and none of it tells you what happens when someone injects a synthetic version of the peptide.
Why an empty list is not a clean record
This is the distinction that matters most on this page, and it is the one that side-effect articles routinely get backwards.
A compound with no reported side effects and a compound with no side-effect data look identical in a search result. They are opposites. One has been measured and came back clean; the other has never been measured at all. MOTS-c is the second kind.
Any page listing MOTS-c side effects with frequencies — "5% report fatigue", "mild injection-site reactions in some users" — is reporting numbers that do not exist. There is no trial from which a percentage could have come: zero human interventional studies of MOTS-c have been published. The denominators were never collected.
MOTS-c has been used less frequently in disease treatment, and no effective method of applying MOTS-c in the clinic has been developed.
Zheng et al., Frontiers in Endocrinology, 2023
MOTS-c
The 16-amino-acid mitochondrial-derived peptide used across the preclinical studies cited here. Research use only, supplied with a batch-matched certificate of analysis.
What the animal work would predict
Absent human data, the preclinical literature is the only place to look for what to watch for. It is unusually broad for a peptide at this stage, and it suggests three areas where an effect would not be a surprise.
- Glucose. MOTS-c activates AMPK and increases muscle glucose uptake in animals. In a person who is not insulin resistant, that pathway points toward hypoglycemia rather than benefit. Nobody has measured it.
- Opposite effects in different tissues. Systemically administered MOTS-c activates CK2 in muscle while suppressing it in fat. A compound that does opposite things in two tissues has an off-target profile that has never been mapped in a person.
- Cell survival and cancer biology. MOTS-c stabilizes Bcl-2, which keeps cells alive, in fatty-liver models — and separately suppresses tumor growth in ovarian cancer models. Both directions are documented. Neither has been characterized for chronic exposure in healthy people.
Systemically administered MOTS-c binds to CK2 in fat and muscle, yet stimulates CK2 activity in muscle while suppressing it in fat.
Kumagai et al., iScience, 2024The same rodent literature also spans radiation-injury, bone-metabolism and gestational-diabetes models. That's unusual breadth for a compound at this stage, and those studies report no obvious toxicity. We think that's worth stating plainly.
Animal work is good at detecting acute organ damage. It's poor at detecting the things that actually end human drug programs: rare reactions, immune responses to a synthetic sequence, and effects that need years to appear.
What has never been established
Before a side-effect profile can exist, a set of much duller facts has to exist first. For MOTS-c, none of them do.
- Human pharmacokinetics. No published half-life, clearance route or bioavailability exists for injected MOTS-c. Nobody can say how long a dose lasts.
- A dose. The numbers circulating in grey-market protocols are scaled from rodent studies, where doses far exceed physiological levels. No human dose-finding study has been published.
- Chronic exposure. The longest animal work runs weeks to months, on intermittent dosing schedules. Nothing addresses years of use in a healthy person.
- Immunogenicity. A synthetic peptide can provoke an antibody response. This has not been tested for MOTS-c in humans.
Note that the mitochondrial peptide class shares this problem. Our class overview covers where each compound sits, and the pattern is consistent: strong mechanism papers, no clinical development.
The effects people do report
Forum and vendor reports mention injection-site irritation, flushing, fatigue, headache and changes in appetite or sleep. Those reports are worth reading as questions, not as data, for four reasons.
They're unblinded and self-selected. They almost always come from someone running two or more compounds at once, which makes attribution impossible. And they rarely note the dose.
They also can't verify what was in the vial. Research-use-only material carries no pharmacopeial identity standard. So an adverse effect you read about may belong to a contaminant, a solvent or an entirely different peptide.
That last one is checkable, which makes it the useful one. A certificate of analysis matched to the batch tells you what the material is, and it is the only part of this picture with a documented answer. See also what research use only means for why that label matters here.
What would change this page
One Phase I trial. Twenty or thirty healthy volunteers, ascending doses, blood work and systematic adverse-event collection, with pharmacokinetics as a secondary endpoint. That study would produce more usable safety information than the entire existing MOTS-c literature.
It has not been run, and the reason is structural rather than scientific. MOTS-c is an endogenous human peptide, which weakens the patent position that normally funds clinical development. The biology attracted an unusual amount of academic attention and none of the commercial machinery that turns biology into trials.
Until that changes, the honest answer to "what are the side effects of MOTS-c" is that nobody has looked. Our complete guide covers what the preclinical work does show, and the SS-31 comparison sets it against the one mitochondrial peptide that has been through registered human trials.
MOTS-c
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- No human safety study of MOTS-c has been published. No trial has administered it and collected adverse events.
- All human data is observational — blood levels in 404 hepatitis B patients, in exercising subjects, in gene-variant carriers.
- Any side-effect list carrying percentages is reporting numbers from a study that does not exist.
- The mechanistic flags worth watching are glucose handling, opposite CK2 effects in muscle and fat, and Bcl-2 stabilization — all from rodent work.
- There is no published human half-life, clearance route or dose-finding study, so protocols in circulation are scaled from mice.
What we're watching
The single event that would change this page is a registered Phase I trial, with pharmacokinetics and systematic adverse-event collection. Nothing smaller helps. More mechanism papers, more plasma-correlation studies and more rodent models leave the safety question exactly where it is.
We're also watching whether anti-doping bodies list mitochondrial-derived peptides explicitly. That usually signals regulators believe use has become widespread.
Frequently asked questions
What are the side effects of MOTS-c?
Unknown. No published trial has given MOTS-c to a person and collected adverse events, so there is no measured side-effect profile. Lists that carry frequencies are not reporting data from any study.
Is MOTS-c safe because no side effects have been reported?
No. Nothing has been reported because nothing has been measured. A compound that was tested and came back clean and a compound that was never tested look identical from outside, and they are not the same thing.
Do the animal studies show toxicity?
They generally report none, at doses well above physiological levels. Rodent studies detect acute organ toxicity reasonably well and are poor at detecting immune responses, rare reactions and effects that take years to appear.
What would be the most likely side effect, mechanistically?
Glucose-related. MOTS-c activates AMPK and increases muscle glucose uptake in animals, so low blood sugar is the plausible effect in someone who is not insulin resistant. That is a prediction from mechanism, not an observation.
References
- Lee, C., Zeng, J., Drew, B. G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009
- Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. https://doi.org/10.1038/s41467-020-20790-0
- Kumagai, H., Kim, S. J., Miller, B., et al. (2024). MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 27(11), 111212. https://doi.org/10.1016/j.isci.2024.111212
- Kumagai, H., Coelho, A. R., Wan, J., et al. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology — Endocrinology and Metabolism, 320(4), E680–E690. https://doi.org/10.1152/ajpendo.00275.2020
- Zheng, Y., Wei, Z., & Wang, T. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 14, 1120533. https://doi.org/10.3389/fendo.2023.1120533
- Lu, H., Fan, L., Zhang, W., et al. (2024). The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Reports, 43(1), 113587. https://doi.org/10.1016/j.celrep.2023.113587
- Lin, C., Luo, L., Xun, Z., et al. (2024). Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. Gut, 73(2), 338–349. https://doi.org/10.1136/gutjnl-2023-330389
- Yin, Y., Li, Y., Ma, B., et al. (2024). Mitochondrial-derived peptide MOTS-c suppresses ovarian cancer progression. Advanced Science, 11(43), e2405620. https://doi.org/10.1002/advs.202405620
- Zhang, Y., Huang, J., Zhang, Y., et al. (2024). The mitochondrial-derived peptide MOTS-c alleviates radiation pneumonitis via an Nrf2-dependent mechanism. Antioxidants, 13(5), 613. https://doi.org/10.3390/antiox13050613
- Yin, Y., Pan, Y., He, J., et al. (2021). The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological Research, 175, 105987. https://doi.org/10.1016/j.phrs.2021.105987
- Yi, X., Hu, G., Yang, Y., Li, J., Jin, J., & Chang, B. (2023). Role of MOTS-c in the regulation of bone metabolism. Frontiers in Physiology, 14, 1149120. https://doi.org/10.3389/fphys.2023.1149120
- U.S. Food and Drug Administration. (2013). Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only